comparemela.com

Page 2 - Jonathan Neely News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Optinose Announces Reporting Date for Fourth Quarter 2023

Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time.

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice -January 18, 2024 at 12:01 pm EST

XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis in two randomized controlled Phase 3 Clinical Trials FDA Supplemental New Drug Application.

Optinose, Inc : Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

Optinose, Inc : Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

County approves Lateral 75 subdivision

OptiNose, Inc (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript

OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript November 9, 2023 OptiNose, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. Operator: Good day and thank you for standing by. Welcome to OptiNose Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.